vs
CORCEPT THERAPEUTICS INC（CORT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CORCEPT THERAPEUTICS INC的1.0倍（$207.3M vs $202.1M），CORCEPT THERAPEUTICS INC净利率更高（12.0% vs -62.0%，领先74.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.1%），CORCEPT THERAPEUTICS INC自由现金流更多（$38.4M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 17.3%）
Corcept Therapeutics是一家制药企业，专注于严重代谢疾病、精神疾病及肿瘤疾病治疗药物的发现、开发与商业化。公司围绕皮质醇过量带来的不良影响展开研究，致力于开发可缓解相关症状的新型化合物，管理团队由首席执行官兼总裁、董事Joseph K. Belanoff医学博士领导。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CORT vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $202.1M | $207.3M |
| 净利润 | $24.3M | $-128.6M |
| 毛利率 | 98.7% | — |
| 营业利润率 | 2.2% | -54.7% |
| 净利率 | 12.0% | -62.0% |
| 营收同比 | 11.1% | 25.9% |
| 净利润同比 | -21.0% | 3.5% |
| 每股收益（稀释后） | $0.20 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $202.1M | $207.3M | ||
| Q3 25 | $207.6M | $159.9M | ||
| Q2 25 | $194.4M | $166.5M | ||
| Q1 25 | $157.2M | $139.3M | ||
| Q4 24 | $181.9M | $164.6M | ||
| Q3 24 | $182.5M | $139.5M | ||
| Q2 24 | $163.8M | $147.0M | ||
| Q1 24 | $146.8M | $108.8M |
| Q4 25 | $24.3M | $-128.6M | ||
| Q3 25 | $19.7M | $-180.4M | ||
| Q2 25 | $35.1M | $-115.0M | ||
| Q1 25 | $20.5M | $-151.1M | ||
| Q4 24 | $30.7M | $-133.2M | ||
| Q3 24 | $47.2M | $-133.5M | ||
| Q2 24 | $35.5M | $-131.6M | ||
| Q1 24 | $27.8M | $-170.7M |
| Q4 25 | 98.7% | — | ||
| Q3 25 | 97.8% | — | ||
| Q2 25 | 98.2% | — | ||
| Q1 25 | 98.5% | — | ||
| Q4 24 | 98.4% | — | ||
| Q3 24 | 98.4% | — | ||
| Q2 24 | 98.5% | — | ||
| Q1 24 | 98.3% | — |
| Q4 25 | 2.2% | -54.7% | ||
| Q3 25 | 4.9% | -106.9% | ||
| Q2 25 | 13.7% | -64.8% | ||
| Q1 25 | 2.2% | -102.6% | ||
| Q4 24 | 13.9% | -74.3% | ||
| Q3 24 | 25.5% | -94.6% | ||
| Q2 24 | 21.7% | -79.1% | ||
| Q1 24 | 20.1% | -151.9% |
| Q4 25 | 12.0% | -62.0% | ||
| Q3 25 | 9.5% | -112.8% | ||
| Q2 25 | 18.1% | -69.0% | ||
| Q1 25 | 13.1% | -108.5% | ||
| Q4 24 | 16.9% | -80.9% | ||
| Q3 24 | 25.9% | -95.7% | ||
| Q2 24 | 21.7% | -89.5% | ||
| Q1 24 | 18.9% | -156.8% |
| Q4 25 | $0.20 | $-1.28 | ||
| Q3 25 | $0.16 | $-1.81 | ||
| Q2 25 | $0.29 | $-1.17 | ||
| Q1 25 | $0.17 | $-1.57 | ||
| Q4 24 | $0.25 | $-1.34 | ||
| Q3 24 | $0.41 | $-1.40 | ||
| Q2 24 | $0.32 | $-1.52 | ||
| Q1 24 | $0.25 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $372.2M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $647.8M | $-80.0M |
| 总资产 | $836.7M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $372.2M | $421.0M | ||
| Q3 25 | $421.7M | $202.5M | ||
| Q2 25 | $342.2M | $176.3M | ||
| Q1 25 | $322.8M | $127.1M | ||
| Q4 24 | $383.3M | $174.0M | ||
| Q3 24 | $380.3M | $150.6M | ||
| Q2 24 | $473.2M | $480.7M | ||
| Q1 24 | $410.8M | $112.3M |
| Q4 25 | $647.8M | $-80.0M | ||
| Q3 25 | $631.9M | $9.2M | ||
| Q2 25 | $635.8M | $151.3M | ||
| Q1 25 | $683.3M | $144.2M | ||
| Q4 24 | $679.6M | $255.0M | ||
| Q3 24 | $638.8M | $346.8M | ||
| Q2 24 | $596.2M | $432.4M | ||
| Q1 24 | $547.9M | $140.3M |
| Q4 25 | $836.7M | $1.5B | ||
| Q3 25 | $823.6M | $1.2B | ||
| Q2 25 | $801.7M | $1.3B | ||
| Q1 25 | $846.5M | $1.3B | ||
| Q4 24 | $840.6M | $1.5B | ||
| Q3 24 | $784.3M | $1.5B | ||
| Q2 24 | $714.6M | $1.6B | ||
| Q1 24 | $655.9M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $38.4M | $-100.8M |
| 自由现金流率自由现金流/营收 | 19.0% | -48.6% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.58× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $38.4M | $-99.8M | ||
| Q3 25 | $54.5M | $-91.4M | ||
| Q2 25 | $43.9M | $-108.3M | ||
| Q1 25 | $5.1M | $-166.5M | ||
| Q4 24 | $59.3M | $-79.3M | ||
| Q3 24 | $73.8M | $-67.0M | ||
| Q2 24 | $41.2M | $-77.0M | ||
| Q1 24 | $23.8M | $-190.7M |
| Q4 25 | $38.4M | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | $43.9M | $-110.7M | ||
| Q1 25 | $5.0M | $-167.8M | ||
| Q4 24 | $59.2M | $-79.5M | ||
| Q3 24 | $72.2M | $-68.6M | ||
| Q2 24 | $40.8M | $-79.0M | ||
| Q1 24 | — | $-193.9M |
| Q4 25 | 19.0% | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | 22.6% | -66.5% | ||
| Q1 25 | 3.2% | -120.5% | ||
| Q4 24 | 32.5% | -48.3% | ||
| Q3 24 | 39.5% | -49.2% | ||
| Q2 24 | 24.9% | -53.7% | ||
| Q1 24 | — | -178.2% |
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.1% | 1.0% | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 0.3% | 1.4% | ||
| Q1 24 | 0.0% | 3.0% |
| Q4 25 | 1.58× | — | ||
| Q3 25 | 2.77× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 1.93× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 0.86× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CORT
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
